Walter & Keenan Financial Consulting Co. MI ADV boosted its stake in Medtronic plc. (NYSE:MDT) by 3.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 22,110 shares of the medical technology company’s stock after purchasing an additional 760 shares during the period. Walter & Keenan Financial Consulting Co. MI ADV’s holdings in Medtronic were worth $1,719,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of MDT. Parkside Financial Bank & Trust grew its position in Medtronic by 22.4% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,146 shares of the medical technology company’s stock worth $102,000 after purchasing an additional 210 shares during the period. BDO Wealth Advisors LLC purchased a new position in shares of Medtronic during the 2nd quarter worth $103,000. Motco boosted its stake in shares of Medtronic by 8.7% during the 2nd quarter. Motco now owns 1,239 shares of the medical technology company’s stock worth $110,000 after acquiring an additional 99 shares during the last quarter. Quadrant Capital Group LLC boosted its stake in shares of Medtronic by 21.5% during the 2nd quarter. Quadrant Capital Group LLC now owns 1,639 shares of the medical technology company’s stock worth $114,000 after acquiring an additional 290 shares during the last quarter. Finally, Blue Chip Partners Inc. purchased a new position in shares of Medtronic during the 3rd quarter worth $118,000. 81.72% of the stock is owned by institutional investors and hedge funds.

Several research analysts have recently weighed in on MDT shares. Royal Bank of Canada dropped their price target on shares of Medtronic from $90.00 to $85.00 and set an “outperform” rating on the stock in a research note on Monday, October 9th. Zacks Investment Research upgraded shares of Medtronic from a “sell” rating to a “hold” rating in a research note on Wednesday, September 6th. SunTrust Banks set a $92.00 price target on shares of Medtronic and gave the stock a “buy” rating in a research note on Sunday, November 19th. Jefferies Group reiterated a “buy” rating and set a $99.00 price target on shares of Medtronic in a research note on Thursday, November 23rd. Finally, Northland Securities reiterated a “hold” rating and set a $80.00 price target on shares of Medtronic in a research note on Wednesday, November 22nd. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and fourteen have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $88.57.

In related news, EVP Bryan C. Hanson sold 16,000 shares of Medtronic stock in a transaction on Friday, December 15th. The shares were sold at an average price of $82.82, for a total transaction of $1,325,120.00. Following the transaction, the executive vice president now owns 88,818 shares in the company, valued at approximately $7,355,906.76. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In the last 90 days, insiders have sold 48,000 shares of company stock worth $3,837,920. 0.31% of the stock is owned by corporate insiders.

Medtronic plc. (NYSE:MDT) opened at $81.54 on Tuesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.05 and a current ratio of 2.40. Medtronic plc. has a one year low of $69.35 and a one year high of $89.72. The firm has a market cap of $110,364.22, a price-to-earnings ratio of 22.34, a P/E/G ratio of 2.25 and a beta of 1.00.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, November 21st. The medical technology company reported $1.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.99 by $0.08. Medtronic had a net margin of 16.93% and a return on equity of 12.63%. The company had revenue of $7.05 billion for the quarter, compared to analysts’ expectations of $7.05 billion. During the same quarter in the previous year, the company earned $1.12 EPS. Medtronic’s revenue for the quarter was down 4.0% on a year-over-year basis. research analysts expect that Medtronic plc. will post 4.77 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, January 19th. Investors of record on Friday, December 29th will be paid a dividend of $0.46 per share. This represents a $1.84 dividend on an annualized basis and a dividend yield of 2.26%. The ex-dividend date is Thursday, December 28th. Medtronic’s dividend payout ratio (DPR) is 50.41%.

TRADEMARK VIOLATION NOTICE: “Medtronic plc. (MDT) Shares Bought by Walter & Keenan Financial Consulting Co. MI ADV” was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://theolympiareport.com/2017/12/26/medtronic-plc-mdt-shares-bought-by-walter-keenan-financial-consulting-co-mi-adv.html.

About Medtronic

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.